Effect of Guselkumab a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients With Active PsA: Results From a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years

Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (10 more authors) (2022) Effect of Guselkumab a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients With Active PsA: Results From a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years. In: Canadian Rheumatology Association Annual Meeting, 02-05 Feb 2022, Online.